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Histological grading is important to treat algorism in pancreatic neuroendocrine 
neoplasms (PNEN). The present study examined the efficacy of contrast-enhanced 
harmonic endoscopic ultrasound (CH-EUS) and time-intensity curve (TIC) analysis of 
PNEN diagnosis and grading. 
Methods 
TIC analysis was performed in 30 patients using data obtained from CH-EUS, and 
histopathological diagnosis was performed via EUS-guided fine needle aspiration or 
surgical resection. The TIC parameters were analyzed by dividing them into G1/G2 and 
G3/NEC groups. Then, patients were classified into non-aggressive and aggressive 
groups and evaluated. 
Results 
Twenty-six patients were classified as G1/G2, and 4 as G3/NEC. From the TIC analysis, 
five parameters of I; echo intensity change, II; time for peak enhancement, III; speed of 
contrast, IV; decrease rate for enhancement, and V; enhancement ratio for node / 
pancreatic parenchyma were obtained. Three of these parameters, I, IV and V, showed 
high diagnostic performance. Using the cutoff value obtained from the receiver operating 
characteristic (ROC) analysis, the correct diagnostic rates of parameter I, IV and V were 
96.7%, 100%, and 100%, respectively, between G1/G2 and G3/NEC. A total of 21 
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patients were classified into the non-aggressive group, and 9 into the aggressive group. 
Using the cutoff value obtained from the ROC analysis, the accurate diagnostic rates of I, 
IV and V were 86.7%, 86.7%, and 88.5%, respectively, between the non-aggressive and 
aggressive groups. 
Conclusion 
CH-EUS and TIC analysis showed high diagnostic accuracy for grade diagnosis of PNEN. 
Quantitative perfusion analysis is useful to predict PNEN grade diagnosis preoperatively. 
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Recently, there has been an increasing number of incidentally discovered 
pancreatic neuroendocrine neoplasms (PNEN) because of high-quality image inspection 
[1,2]. Especially, endoscopic ultrasound (EUS) is a useful technique in detecting small 
PNEN [3,4]. PNEN include various histological malignancies, and the WHO defined the 
pathological classifications as G1, G2, G3, and neuroendocrine carcinoma (NEC) 
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according to the mitotic and Ki-67 index in 2017. The prognosis varies greatly depending 
on the grade, and treatment strategies are different among G1, G2, G3, and NEC. Though 
surgical resection is the main treatment for PNEN, limited resection, such as enucleation 
or resection without lymph node dissection, is acceptable in cases of low-grade PNEN 
[5], and grade diagnosis is also necessary for the selection of chemotherapy in 
unresectable cases. Thus, grade diagnosis of PNEN is important to determine the 
appropriate treatment. On the other hand, patients with G1/G2 PNEN sometimes have 
distant metastasis, however, unfortunately, it is currently difficult for the grade diagnosis 
to distinguish these patients from other patients without metastasis. 
There are several reports describing the effectiveness of grade diagnosis before 
treatment with EUS-guided fine needle aspiration (EUS-FNA) [6-9]. However, there was 
a report in which the Ki-67 index varies within the tumor and does not necessarily mean 
that the hotspot is punctured [10]. Grade diagnosis should not be determined when tumor 
cells are not sufficiently contained in biopsy specimens. Therefore, another evaluation 
method is necessary in case pathological evidence for grading diagnosis cannot be 
acquired with EUS-FNA.  
Contrast-enhanced harmonic EUS (CH-EUS) allows us to depict micro-
vasculatures in real time. In addition, temporal change of the echo enhancement intensity 
can be measured, and a time-intensity curve (TIC) can be achieved. With percutaneous 
contrast-enhanced ultrasound, the usefulness of TIC analysis has been reported in breast 
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tumors, renal masses, and liver tumors [11-13]. For pancreatic diseases, EUS is effective 
because it can approach and perform detailed observation. It has been reported that CH-
EUS using TIC analysis is effective in differentiating various pancreatic tumors [14,15]. 
In addition, in PNEN, several papers reported the effectiveness of CH-EUS for evaluation 
of malignant potential. [16, 17]. However, there are no extensive reports about the 
relationship between PNEN and the accuracy of CH-EUS with TIC analysis.  
We retrospectively analyzed a series of PNENs to determine whether CH-EUS 
with TIC analysis predicted the pathological grade and the malignant potential in G1/G2 





Patients and study design 
Eligibility criteria was the following: (i) PNEN for which CH-EUS and TIC 
analysis had been performed and (ii) a pathologically proven PNEN grade with evaluation 
specimens acquired via surgical resection or EUS-FNA. Endoscopic, radiological, and 
clinical data were retrospectively extracted from clinical records of all patients. 
Patients pathologically diagnosed as PNEN G1/G2 via surgical resection or as 
PNEN G3/NEC via EUS-FNA at our institution from November 2009 and March 2018 
were included in the analysis. These pathological samples were carefully examined by a 
pathologist according to the WHO 2017 classification. The tumor staging of all patients 
was evaluated with computed tomography (CT), based on the European Neuroendocrine 
Tumor Society (ENET) guidelines. In addition to the WHO 2017 classification, the 
subjects were analyzed by dividing them into the non-aggressive and aggressive group 
more clinically. Tumors were thought to be aggressive when there were morphological 
findings of an advanced disease (close organ involvement, lymph node involvement, and 
distant organ metastasis) or histological findings of a G3/NEC. 
The study was approved by the review board of our institution, and informed 
consent regarding CH-EUS with TIC analysis was obtained from all patients. 
 
EUS-FNA and pathological evaluation 
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EUS-FNA was performed using convex echoendoscopes (GF-UCT260; 
Olympus Optical Co. Ltd., Tokyo, Japan) with 19-, 22-, or 25-G needles. Immediately 
after tissue collection, a part of aspirated material was examined by a cell pathologist 
through a Diff-Quick staining method to ensure that the specimen was adequate as rapid 
on-site evaluation. As a surgical specimen, the remaining material was fixed in 10% 
formalin in a specimen bottle. If the specimens were too small for histopathological 
diagnosis, the specimens were centrifuged and then seated in paraffin for cell-block 
analysis.  
The formalin-fixed FNA and surgical specimens were processed into paraffin, 
and staining of 5-μm sections with hematoxylin and eosin was performed for 
conventional histology and evaluated according to the WHO 2017 guidelines. 
Immunohistochemistry was performed using the primary antibodies against CD31, 
chromogranin A, synaptophysin, and Ki-67. The proliferation index for Ki-67 was 
evluated by the WHO 2017 guidelines. 
 
CH-EUS protocol 
EUS was performed using electronic radial echoendoscopes (GF-UE260-AL5; 
Olympus Optical Co. Ltd., Tokyo, Japan) or convex echoendoscopes (GF-UCT260). The 
apparatus used was ProSound α10 or F75 (Hitachi Aloka Co., Tokyo, Japan). 
 
 8 
In case of suspected PNEN by B-mode EUS, CH-EUS was employed. An 
extended harmonic detection mode in which the filtered fundamental frequency and 
second harmonic component frequency were combined with a transmission frequency of 
4.7 MHz was used. After intravenous administration of the contrast agent Sonazoid 
(Daiichi Sankyo, Tokyo, Japan), bloodstream of micro vessels in the tumor was evaluated. 
Sonazoid was a second-generation contrast agent for ultrasound containing 
perfluorobutane microbubbles with a median diameter of 2–3 µm. One vial of Sonazoid 
had 16 µL of perfluorobutane in 2 mL of distilled water, which was administered with 
transvenous injection at 0.015 mL/kg. After injection, the lesion suspected of PNEN was 
continuously observed for 120 seconds, and its enhancement was compared with that of 
the surrounding pancreatic parenchyma. 
 
TIC analysis 
The digital CH-EUS data were recorded continuously for 120 seconds following 
administration of the contrast medium. Subsequently, those data stored on the hard drive 
were retrieved and analyzed. Two circular regions of interest (ROIs) were placed in the 
tumor and surrounding parenchyma of the pancreas. To prevent incorrect settings, the 
position of the ROI was determined by two endoscopists with experience in CH-EUS. No 
knowledge of the final diagnosis was provided to these two endoscopists. The position of 
the ROI was calibrated to the respiratory movement of the patient. The size of ROI was 
 
 9 
decided according to the tumor size, and ROI was settled as widely as possible to cover 
the entire tumor. If the tumor contained cystic change, the ROI was placed avoiding cystic 
area. Especially in case with a large tumor, the content was sometimes heterogeneous 
with solid and cystic part. In such a case, ROI was placed at the largest solid part of 
several solid parts. The echo intensity of the ROI was quantified, and a TIC was computed 
with a software program embedded in the ultrasound imaging system. 
The following parameters were measured from the TIC (Figure 1): 
I. Echo intensity change 
II. Time for peak enhancement 
III. Speed of contrast 
IV. Decrease rate for enhancement 
V. Enhancement ratio for node / pancreatic parenchyma 
These parameters were compared among the groups G1/G2 and G3/NEC. 
Histopathological examination findings from excised specimens provided the reference 
criteria. In addition to the comparison of parameters among histopathological grading, 
differences between the non-aggressive and aggressive groups and that between cystic 
PNEN and solid PNEN were analyzed.  
Statistical data was analyzed using the JMP software program version 13.0 (SAS 
Institute, Cary, North Carolina, USA). Categorical values were compared using Fisher’s 
exact test. Continuous values were presented as median and interquartile range and 
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compared using the Mann-Whitney U test. The Youden index calculation was used, and 
the cutoff values were determined by a receiver operating characteristic (ROC) analysis 







EUS was performed on 77 patients suspected of PNEN. Fifty-one patients 
underwent EUS-FNA or surgical resection, and were diagnosed with PNEN 
pathologically. Grade diagnosis was possible in 40 patients. Of the 40 patients, 30 in 
whom both grade diagnosis and TIC analysis were applicable were enrolled in this study 
(Figure 2). 
The clinical characteristics of the 30 patients are shown in Table 1. All 30 patients 
underwent surgical resection or EUS-FNA, and the final diagnosis was determined via 
the pathological findings. A total of 19 patients were classified as G1, 7 patients as G2, 
and 4 patients as G3/NEC. There were no significant differences with regard to the 
clinical and morphological findings observed among the three groups. There was a 
significant difference in tumor size and stage according to the ENET guideline.  
Of all 30 patients, 24 patients underwent surgical resection after EUS-FNA. Ki-
67 could not be measured in FNA specimens in 13 patients, and the correct diagnostic 
rate for PNEN grade diagnosis via EUS-FNA was 37.5% (9/24). Therefore, the grade 
diagnosis was obtained via both EUS-FNA and surgical resection in 9 patients and via 
only surgical resection in 17 patients. Of these 26 patients, 19 was G1, and 7 was G2. 
Remaining four of G3/NEC patients were diagnosed via only EUS-FNA. 
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The subjects were analyzed by dividing them into aggressive and non-aggressive 
groups as shown in Table 2. A total of 21 patients were classified in the non-aggressive 
group and 9 patients were classified in the aggressive group. No significant differences 
were noted regarding the clinical and morphological factors observed between the two 
groups. There was a significant difference in tumor size and stage ENET.  
Cystic degeneration was observed in 11 of 30 patients. The rate of cystic 
degeneration was 38.5% in G1/G2 (10/26) and 25% in G3/NEC (1/4) (P=0.59). The rate 
of cystic degeneration was 33.3% (7/21) in the non-aggressive group and 44.4% (4/9) in 
aggressive group (P=0.56). 
TIC parameters of PNEN 
Typical findings and TICs of G1 and G3/NEC cases are shown in Figures 3 and 
4. 
All tumors were contrasted at the early stage, and then the contrast weakened 
over time. G1 was intensely contrasted at an early stage, and the contrast lasted 
interminably. G3/NEC was contrasted weakly at an early stage, and its level declined 
quickly. G2 had roughly a middle contrast effect. Non-significant adverse events were 
occurred associated with CH-EUS. 
TIC analysis quantified the contrast effect as a level and was evaluated. 
Considering the G1/G2 and G3/NEC groups, the three parameters, I; echo intensity 
change, IV; decrease rate for enhancement, and V; enhancement ratio for node / pancreatic 
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parenchyma, showed high diagnostic performance (Table 3). The cutoff values 
determined by ROC analysis between G1/G2 and G3/NEC were 92.5, 0.76, and 0.92 for 
parameter I, IV, and V, respectively. Using the cutoff value obtained by ROC analysis, the 
correct diagnostic rates differentiating G1/G2 and G3/NEC of parameter I, IV, and V were 
96.7%, 100%, and 100%, respectively (Table 4). 
Considering the non-aggressive and aggressive groups, the three parameters, I, 
IV, and V, showed high diagnostic performance (Table 5). The cutoff values determined 
by ROC analysis between the non-aggressive and aggressive groups were 95.2, 0.645, 
and 0.928 for parameter I, IV, and V, respectively. Using the cutoff value obtained by 
ROC analysis, the accurate diagnostic rates differentiating the non-aggressive and 
aggressive groups of parameter I, IV, and V were 86.7%, 86.7%, and 88.5%, respectively 
(Table 6). 
In addition, the G1/G2 group included 21 patients from the non-aggressive group 
and 5 patients from the aggressive group. The cut-off values obtained by ROC analysis 
between the non-aggressive and aggressive groups within the G1/G2 group were 138.8, 
0.428, and 1.362 for parameter I, IV, and V, respectively. Using the cutoff values obtained 
by ROC analysis, the accurate diagnostic rates differentiating the non-aggressive and 
aggressive groups for parameter I, IV, and V were 46.2%, 73.1%, and 45.8%, respectively, 
in the G1/ G2 group. 
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 The median values of the parameter I, IV, and V in cystic PNEN were 136, 0.37, 
and 1.79. Those in solid PNEN were 120, 0.48, and 1.36, respectively. There was no 
significant difference between cystic and solid PNEN on each TIC parameter. 
Comparison of grade diagnostic ability between EUS-FNA and TIC analysis 
 Of 24 patients undergoing both EUS-FNA and surgical resection, 17 patients 
were G1 and seven patients were G2. The cut-off values obtained by ROC analysis 
between the 17 patients of G1 and the 7 patients of G2 were 103, 0.37, and 2.03 for 
parameter I, IV, and V. Using the cutoff values obtained by ROC analysis, the accurate 
diagnostic rates differentiating between the two groups was 76.9%, 65.4%, and 75.0%. 





The prognosis of PNEN differs depending on the pathological grade. In several 
guidelines of PNEN, a pathological grade diagnosis is recommended to determine 
treatment strategies, especially in the differential diagnosis between G1/G2 and G3/NEC 
[5,17]. Several reports described the effectiveness of pathological grading via EUS-FNA 
in preoperative and unresectable cases. The accuracy of pathological grading was 
reported to be 69.2–87.5% [8,9,18-20]. However, the controversies on the diagnostic 
ability of EUS-FNA for pathological grading of PNEN remain, because the samples 
obtained through EUS-FNA or liver biopsy are sometimes so small that pathological 
grading is difficult, and underestimation might occur. 
Several studies have reported the effectiveness of CH-EUS in patients with 
PNEN. Kitano et al. reported that CH-EUS depicted hypervascular enhancement 
diagnosed as PNEN with a sensitivity and specificity of 78.9% and 98.7%, respectively 
[3]. Ishikawa et al. reported the heterogeneous ultrasonographic texture as malignant 
PNEN and that the sensitivity, specificity, and accuracy of conventional EUS for 
malignancy were 90.5%, 85.0%, and 87.8%, respectively [16]. Palazzo et al. reported that 
CH-EUS is accurate for predicting aggression by evaluating heterogeneous patterns 
within the PNEN and the overall accuracy, sensitivity, specificity, positive predictive 
value, and negative predictive value of CH-EUS for the diagnosis of tumor 
aggressiveness were 86%, 96%, 82%, 71%, and 98%, respectively [17]. However, no 
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study evaluated the usefulness of CH-EUS with TIC analysis for pathological grading of 
PNEN. This is the first study using CH-EUS with TIC analysis for malignancy prediction 
of PNEN.  
In most studies in which the effectiveness of CH-EUS was estimated, evaluation 
of the contrast pattern depends on the intuition of the operator, and a large difference 
among operators or facilities is sometimes observed. In TIC analysis, quantitative blood 
flow dynamics can be evaluated by setting the ROI and measuring the contrast intensity. 
We found a correlation between pathological grade and CH-EUS with TIC analysis. 
Especially, the echo intensity reduction rate was extremely different between G1/G2 and 
G3/NEC. High diagnostic accuracy could be obtained using the cutoff value determined 
from the ROC analysis, and the grade could be predicted from the echo intensity reduction 
rate. CH-EUS with TIC analysis is useful as one of the diagnostic modalities for the 
pathological grading of PNEN. In addition, the grade diagnostic ability was compared 
between EUS-FNA and TIC analysis in this study. Although it was limited in analysis 
between G1 and G2, the grade diagnostic ability of TIC analysis superior to that of EUS-
FNA. 
However, it is sometimes difficult to differentiate PNEN and pancreatic cancer 
only via imaging modalities such as contrast enhanced computed tomography and 
magnetic resonance imaging. We think that the differentiation using every diagnostic 
imaging modality including CH-EUS is difficult in cases of no findings with hyper 
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vascular tumor which is a typical finding of PNEN. Fortunately, there were no cases who 
were misdiagnosed with pancreatic cancer preoperatively in this study. However, EUS-
FNA is necessary for differentiation between pancreatic neuroendocrine tumor and 
pancreatic cancer in such cases. 
In contrast, the issue on the choice of treatment strategy according to 
pathological grading is that the prediction of G1 and G2 cases with distant metastasis due 
to high biological malignancy is impossible. In our study, two of seven (28.5%) patients 
with G2 (one, liver metastasis; one, liver and bone metastasis) had distant metastasis of 
the liver (Table 1). Therefore, the presence or absence of distant metastasis is not always 
associated with pathological grade. We think that the results are influenced by 
microvessel density (MVD) within the tumor. MVD has been suggested a prognostic 
parameter in many malignant tumors. In PNEN, it has been reported that MVD was 
significantly higher in well-differentiated benign endocrine tumors than in tumors of 
uncertain behavior and carcinomas [21-23]. Palazzo et al. compared MVD between 
PNEN with or without distant metastasis, and there were significant differences between 
them, irrespective of the pathological grade [17]. Therefore, we think that TIC analysis 
based on CH-EUS findings may be able to evaluate biological malignancy of PNEN in 
the patients with G1/G2. Actually, we could differentiate G1 and G2 with high biological 
malignancy from those with low biological malignancy in this study by parameter IV; 
decrease rate for enhancement (73.1%). 
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Recently, several papers reported that cystic PNEN tend to be biologically less 
aggressive compared with their solid counterparts [24-26]. 11 of 30 cases had cystic 
degeneration in this study. However, there was no significant relationship between the 
presence of cystic degeneration and tumor aggressiveness. Although we also evaluated 
the differentiation of TIC parameters between cystic PNEN and solid PNEN, significant 
difference was not found in each TIC parameter. 
This study had several limitations. First, our study was retrospective with results 
from a single institution. Owing to the small sample size, especially for G3/NEC, only 4 
cases could be analyzed. Second, the diagnosis of the patients with G3/NEC were 
determined via only EUS-FNA. However, the misdiagnosis of pathological grading by 
EUS-FNA is mainly due to underestimation, and G3/NEC had less possibility of 
underestimation. Third, there is a technical problem. There are several cases in which it 
is difficult to continuously visualize the target tumor or pancreatic parenchyma with EUS 
and the TIC could not be measured. Fourth, this study mixed G3 and NEC as one group. 
The WHO 2017 grading system distinguishes G3 and NEC pathologically. However, 
recent papers written under pathological classification before WHO 2017 mixed G3 and 
NEC. These papers showed poor prognosis in G3, including NEC, compared with G1/G2. 
Several papers reported the relationship between micro vessel density (MVD) and PNEN 
[17,22,27,28]. In those papers, MVD has a significant relationship with the Ki-67 index, 
which is significantly higher in G3/NEC than in G1/G2. In addition, the results of the TIC 
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study are reported to be affected by MVD [15,29,30]. Therefore, we think that 
differentiation between G1/G2 and G3/NEC by TIC analysis is reasonable and feasible. 
In conclusion, CH-EUS can be employed for the small PNEN, in which enough 
sample for pathological grading is difficult to obtain, and TIC facilitates accurate 
quantitative analysis of the CH-EUS results. The combination of CH-EUS with TIC 
analysis and EUS-FNA and/or surgery has the potential of establishing a new treatment 
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Table 1 Characteristics of patients with PNEN, who underwent contrast-enhanced 
harmonic endoscopic ultrasonography (CH-EUS). 
    
  G1/G2 n=26 G3/NEC n=4 P value 
Gender     0.7041 
  Male 9 1  
  Female 17 3  
Mean age median 
(IQR)1 
65.5 (45-69.5) 71.5 (50.25-83.75) 0.2712 
Functioning tumor   0.8961 
  Insulinoma 3 1  
  Gastrinoma 1 -  
Nonfunctioning 
tumor 
19 3  
MEN type 1 3 -  
Size2, median 
(mm)(IQR)1 
15 (12.75-34.25) 33.5 (23-41.75) 0.1113 
Stage ENET   0.0010  
  Ⅰ 15 -  
  Ⅱa/Ⅱb 7 -  
  Ⅲa/Ⅲb 2 -  
  Ⅳ 2 4   
    
NEC, Neuroendocrine carcinoma; IQR, interquartile range; MEM, Multiple Endocrine 
Neoplasia 
ENET, European Neuroendocrine Tumor Society 
1 Values of median and IQRs were statistically calculated using the JMP software programs. 





Table 2 Characteristics of patients, with PNEN with non aggressive and aggresive, 
who underwent contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS). 
    
  non aggressive n=21 aggressive n=9 P value 
Gender     0.3980  
  Male 8 2  
  Female 13 7  
Mean age median 
(IQR)1 
66(46-70) 66(33.5-76) 1.0000  
Functioning tumor   0.4479 
  Insulinoma 3 1  
  Gastrinoma 1 -  
Nonfunctioning 
tumor 
15 8  
MEN type 1 2 -  
Size2, median 
(mm)(IQR)1 
15(11.5-26) 35(33-57) 0.0003 
Stage ENET   <0.0001 
  Ⅰ 15 -  
  Ⅱa/Ⅱb 6 1  
  Ⅲa/Ⅲb - 2  
  Ⅳ - 6   
    
IQR, interquartile range; MEM, Multiple Endocrine Neoplasia 
ENET, European Neuroendocrine Tumor Society 
1 Values of median and IQRs were statistically calculated using the JMP software programs. 





Table 3 Time-intensity curve analysis from patients with PNEN, who underwent contrast-
enhanced harmonic endoscopic ultrasonography (CH-EUS) . 
    









75.92 (53.79-92.15) 0.0031 
Time for peak 
enhancement, s 
10.11 (7.37-13.57) 10.61 (7.37-20.29) 0.6473 
Speed of contrast, 
level/s 
13.33 (9.56-20.16) 7.39 (3.40-11.35) 0.0546 
Decrease rate for 
enhancement, % 
0.37 (0.28-0.48) 0.82 (0.77-0.87) 0.0017 
Enhancement ratio 
for node / pancreatic 
parenchyma 
1.51 (1.28-1.85) 0.77 (0.62-0.92) 0.0237 
    




Table 4 Diagnostic performance of time-intensity curve parameters between PNEN 
G1/G2 and G3/NEC 



























100 96.2 80 100 96.7 
 59.5-100 89.9-96.2 47.6-80 93.5-100 85.9-96.7 





100 100 100 100 100 
 63.5-100 94.4-100 63.5-100 94.4-100 90.3-100 
 4/4 26/26 4/4 26/26 30/30 
Enhanceme




100 100 100 100 100 
 43.1-100 95.3-100 43.1-100 95.3-100 91.2-100 
  2/2 24/24 2/2 24/24 26/26 
      




Table 5 Time-intensity curve analysis from patients with PNEN non-aggressive group or 
aggressive group, who underwent contrast-enhanced harmonic endoscopic ultrasonography 
(CH-EUS) . 
    









92.5 (59.72-129.97) 0.0099 
Time for peak 
enhancement, s 
9.31 (6.73-12.67) 13.43 (8.4-14.5) 0.1606 
Speed of contrast, 
level/s 
13.68 (11.31-21.62) 8.02 (5.29-12.73) 0.0113 
Decrease rate for 
enhancement, % 
0.35 (0.28-0.46) 0.64 (0.40-0.82) 0.0087 
Enhancement ratio 
for node / pancreatic 
parenchyma 
1.46 (1.26-1.83) 1.36 (0.77-1.80) 0.2979 
    




Table 6 Diagnostic performance of time-intensity curve parameters for PNEN non-aggressive 
group or aggressive group 

























55.6 100 100 84.0  86.7 
 34.5-55.6 91.0-100 62.1-100 76.4-84.0 74.0-86.7 




55.6 100 100 84 86.7 
 34.5-55.6 91.0-100 62.1-100 76.4-84.0 74.0-86.7 
 5/9 21/21 5/5 21/25 26/30 
Enhancement 
ratio for node 
/ pancreatic 
parenchyma 
40.0  100 100 87.5 88.5 
 14.8-40.0 94.0-100 37.1-100 82.3-87.5 78.8-88.5 
  2/5 21/21 2/2 21/24 23/26 
      













Figure and Figure Legends 
 
Figure 1. Schematic of a time-intensity curve showing the measured parameters 
Ipeak − Ibase, echo intensity change 
tpeak, time to contrast enhancement 
(Ipeak − Ibase)/tpeak, speed of contrast 
(Ipeak − I120)/Ipeak, decrease rate for enhancement 
(Ipeak − Ibase, for the nodule)/ (Ipeak − Ibase, for the parenchyma), enhancement ratio 










Figure 3. Pancreatic endocrine tumor in the G1/G2 group within the pancreatic tail a. 
Contrast-enhanced computed tomography image b. Fundamental B-mode endoscopic 
ultrasonography (EUS) shows a hypoechoic lesion c. A pre-enhancement image d. EUS 
image at the peak of contrast enhancement. The yellow and purple circles show the 
regions of interest (ROIs) in the tumor and pancreatic parenchyma, respectively, both of 
which were enhanced e. EUS image obtained 120 s after Sonazoid injection, revealing 
continued enhancement in both the tumor (yellow circle) and pancreatic parenchyma 
(purple circle) f. Time-intensity characteristics of the tumor (yellow line) and pancreatic 
parenchyma (purple line). At 120 s after injection, the echo intensity from the peak 
decreased in the pancreatic tumor rather than the pancreatic parenchyma. When 
analyzing the TIC, the echo intensity change was 128.75, decrease rate for enhancement 





Figure 4. A pancreatic endocrine tumor in the G3/NEC group within the pancreatic 
body. a. Contrast-enhanced computed tomography image b. Fundamental B-mode 
endoscopic ultrasonography (EUS) showed a hypoechoic lesion c. A pre-enhancement 
image d. EUS image at the peak of contrast enhancement. The yellow and purple circles 
show the regions of interest (ROIs) in the tumor and pancreatic parenchyma, 
respectively, both of which were enhanced. e. EUS image obtained 120 s after Sonazoid 
injection, revealing continued enhancement in both the tumor (yellow circle) and 
pancreatic parenchyma (purple circle) f. Time-intensity characteristics of the tumor 
(yellow line) and pancreatic parenchyma (purple line). At 120 s after injection, the 
enhanced echo intensity of the pancreatic parenchyma was slightly reduced, whereas 
that of the tumor was markedly decreased from the peak intensity. When analyzing TIC, 
the echo intensity change was 92.5, decrease rate for enhancement was 85.5, and 
enhancement ratio for node / pancreatic parenchyma was 0.92. 
 
